Use of intravenous sotalol in newborns with supraventricular
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Supraventricular tachycardia (SVT) in the newborn population is a common arrhythmia that can at times be difficult to treat, with long-standing persistent SVT resulting in tachycardia-induced cardiomyopathy. Certain arrhythmic substrates, like ectopic atrial tachycardia (EAT), can be refractory to commonly used antiarrhythmics and may not be responsive to cardioversion. It is therefore important to identify a host of drugs that can quickly terminate arrhythmias.Class III antiarrhythmics are often used in infants with SVT that is unresponsive to typical first-line agents such as beta blockers or sodium channel blockers, though oral preparations are suboptimal given the pharmacokinetics. There are limited data describing the efficacy and dosage of intravenous (IV) sotalol for the management of tachycardia in the pediatric population, with the current literature focusing on children ?2 years old. In this report, we describe a case series of the use of IV sotalol for the treatment of neonatal EAT and atrioventricular reentrant tachycardia....

http://bit.ly/2uY2khZ
Like
Comment
Share